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We report a case of a 70-year-old woman, with a 56 
pack-year smoking history, who presented with an 8-week 
history of progressively worsening shortness of breath, 
cough, pleuritic chest pain, and an 18-pound weight loss. A 
chest radiograph showed a large opacification suggestive of a 
right-sided mediastinal mass. Positron emission tomography 
computed tomography demonstrated a large heterogeneous, 
intensely F-18-fluorodeoxyglucose-avid right-sided poste-
rior mediastinal mass, measuring 74 × 60 mm in transaxial 
dimensions, 114 × 18 mm in coronal dimensions. The mass 
extended from the level of the aortic arch to the left atrium 
inferiorly and caused significant compression and displace-
ment of the proximal and midesophagus and the left atrium, 
with no evidence of disease outside the thorax. Bronchoscopic 
biopsy confirmed small-cell lung cancer (SCLC). Her radio-
graphic studies revealed limited disease SCLC, and concur-
rent chemoradiotherapy was recommended.
The patient was initiated on chemotherapy with cispla-
tin plus etoposide; radiotherapy was scheduled to start with 
her second cycle. On day 8 of cycle 1, she presented to clinic 
for follow-up with no complaints. Her serum biochemistry 
was significant for a uric acid level of 12.1 mg/dl; lactate 
dehydrogenase 502 IU/liter; sodium level of 127 mmol/liter; 
potassium, 4.8 mmol/liter, 25% higher than her baseline (3.5 
mmol/liter), bicarbonate, 22 mmol/liter; creatinine, 3.3 mg/dl 
(upper limit of normal 1.2); phosphorus, 5.5 mg/dl, and cal-
cium, 9.7 mg/dl. On the basis of her elevated serum uric acid, 
potassium, phosphorus, and creatinine more than 1.5 times 
upper limit of normal, she met criteria for laboratory and clin-
ical tumor lysis syndrome (TLS) (Table 1).1 She was admitted 
for intravenous hydration, and received treatment with allo-
pourinol and rasburicase (hypouricosuric agent). Her renal 
function improved with treatment and she was discharged 
after a 3-day hospitalization. A postcycle 1 chest computed 
tomography scan revealed a significant decrease in the size 
of her mediastinal mass (Fig. 1), which was most likely the 
source of her TLS.
TLS is a life-threatening oncologic emergency encoun-
tered more frequently after treatment of hematologic malig-
nancies than solid tumors.2 TLS develops usually in patients 
with rapidly dividing cancers, which are responsive to treat-
ment, like non-Hodgkin’s lymphoma or acute leukemia. Of the 
various histologic types of lung cancer, small cell is the most 
proliferative, with a high Ki-67 reflecting its proliferation rate 
and a very high response to chemotherapy.3–5 TLS has been 
described previously in patients with extensive stage SCLC, 
after initiation of treatment with chemotherapy. Patients with 
limited-stage SCLC with evidence of bulky or rapidly pro-
gressive disease should be monitored and considered for TLS 
prophylaxis with hydration and hypouricosuric agents, such as 
allopurinol, particularly before the first cycle.
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FIGURE 1. A, Transaxial image 
before treatment initiation, (B) 
transaxial image after the first cycle 
of chemotherapy and the TLS. TLS, 
tumor lysis syndrome.
TABLE 1.  Cairo and Bishop Definition of Tumor Lysis syndrome
Laboratory tumor lysis syndrome: changes in two or more of the following parameters (need to be within 3 days before or 7 days after initiation of treatment)
 Uric acid ≥ 476 μmol/liter (8 mg/dl) or 25% increase from baseline
 Calcium ≤ 1.75 μmol/liter (7 mg/dl) or 25% decrease from baseline
 Potassium ≥ 6.0 mmol/liter (6 meq/liter) or 25% increase from baseline
 Phosphate ≥ 1.45 mmol/liter (4.5 mg/dl) or 25% increase from baseline
Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus at least one of the following:
 Serum creatinine > 1.5 times the upper limit of normal
 Cardiac arrhythmia or sudden death
 Seizure
